multiple myeloma

Summary

Summary: A malignant tumor of plasma cells usually arising in the bone marrow; characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria, and anemia.

Top Publications

  1. pmc Initial genome sequencing and analysis of multiple myeloma
    Michael A Chapman
    The Eli and Edythe L Broad Institute, 7 Cambridge Center, Cambridge, Massachusetts 02412, USA
    Nature 471:467-72. 2011
  2. pmc Proteasome inhibitors in multiple myeloma: 10 years later
    Philippe Moreau
    Hematology Department, University Hospital Hotel Dieu, Nantes, France
    Blood 120:947-59. 2012
  3. pmc Improved survival in multiple myeloma and the impact of novel therapies
    Shaji K Kumar
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 111:2516-20. 2008
  4. pmc Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma
    Jonathan J Keats
    Comprehensive Cancer Center, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA
    Cancer Cell 12:131-44. 2007
  5. pmc Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma
    Christina M Annunziata
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Cancer Cell 12:115-30. 2007
  6. pmc Clonal competition with alternating dominance in multiple myeloma
    Jonathan J Keats
    Comprehensive Cancer Center, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA
    Blood 120:1067-76. 2012
  7. pmc Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development
    Flavia Pichiorri
    Department of Molecular Virology, Comprehensive Cancer Center, Ohio State University, Columbus, 43210, USA
    Cancer Cell 18:367-81. 2010
  8. pmc Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides
    Jan B Egan
    Division of Hematology Oncology, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA
    Blood 120:1060-6. 2012
  9. ncbi International uniform response criteria for multiple myeloma
    B G M Durie
    Aptium Oncology, Inc, Cedars Sinai Outpatient Cancer Center, Los Angeles, CA 90048, USA
    Leukemia 20:1467-73. 2006
  10. ncbi International staging system for multiple myeloma
    Philip R Greipp
    Mayo Clinic College of Medicine and Eastern Cooperative Oncology Group, Rochester, MN, USA
    J Clin Oncol 23:3412-20. 2005

Detail Information

Publications386 found, 100 shown here

  1. pmc Initial genome sequencing and analysis of multiple myeloma
    Michael A Chapman
    The Eli and Edythe L Broad Institute, 7 Cambridge Center, Cambridge, Massachusetts 02412, USA
    Nature 471:467-72. 2011
    b>Multiple myeloma is an incurable malignancy of plasma cells, and its pathogenesis is poorly understood. Here we report the massively parallel sequencing of 38 tumour genomes and their comparison to matched normal DNAs...
  2. pmc Proteasome inhibitors in multiple myeloma: 10 years later
    Philippe Moreau
    Hematology Department, University Hospital Hotel Dieu, Nantes, France
    Blood 120:947-59. 2012
    Proteasome inhibition has emerged as an important therapeutic strategy in multiple myeloma (MM)...
  3. pmc Improved survival in multiple myeloma and the impact of novel therapies
    Shaji K Kumar
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 111:2516-20. 2008
    ..8 vs 29.9 months; P < .001). In this study, we demonstrate improved outcome of patients with myeloma in recent years, both in the relapsed setting as well as at diagnosis...
  4. pmc Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma
    Jonathan J Keats
    Comprehensive Cancer Center, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA
    Cancer Cell 12:131-44. 2007
    ..An integrated analysis of high-density oligonucleotide array CGH and gene expression profiling data from 155 multiple myeloma samples identified a promiscuous array of abnormalities contributing to the dysregulation of NF-kappaB in ..
  5. pmc Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma
    Christina M Annunziata
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Cancer Cell 12:115-30. 2007
    Mechanisms of constitutive NF-kappaB signaling in multiple myeloma are unknown. An inhibitor of IkappaB kinase beta (IKKbeta) targeting the classical NF-kappaB pathway was lethal to many myeloma cell lines...
  6. pmc Clonal competition with alternating dominance in multiple myeloma
    Jonathan J Keats
    Comprehensive Cancer Center, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA
    Blood 120:1067-76. 2012
    ..genomic analysis of samples collected at different points during the disease course of 28 patients with multiple myeloma, we found that the genomes of standard-risk patients show few changes over time, whereas those of ..
  7. pmc Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development
    Flavia Pichiorri
    Department of Molecular Virology, Comprehensive Cancer Center, Ohio State University, Columbus, 43210, USA
    Cancer Cell 18:367-81. 2010
    In multiple myeloma (MM), an incurable B cell neoplasm, mutation or deletion of p53 is rarely detected at diagnosis...
  8. pmc Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides
    Jan B Egan
    Division of Hematology Oncology, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA
    Blood 120:1060-6. 2012
    ..sequencing (WGS) on 4 purified tumor samples and patient germline DNA drawn over a 5-year period in a t(4;14) multiple myeloma patient...
  9. ncbi International uniform response criteria for multiple myeloma
    B G M Durie
    Aptium Oncology, Inc, Cedars Sinai Outpatient Cancer Center, Los Angeles, CA 90048, USA
    Leukemia 20:1467-73. 2006
    ..It is anticipated that the International Response Criteria for multiple myeloma will be widely used in future clinical trials of myeloma.
  10. ncbi International staging system for multiple myeloma
    Philip R Greipp
    Mayo Clinic College of Medicine and Eastern Cooperative Oncology Group, Rochester, MN, USA
    J Clin Oncol 23:3412-20. 2005
    There is a need for a simple, reliable staging system for multiple myeloma that can be applied internationally for patient classification and stratification.
  11. pmc International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
    R Fonseca
    Department of Hematology Oncology, Mayo Clinic, 13400 East Shea Boulevard, Scottsdale, AR 85259 5494, USA
    Leukemia 23:2210-21. 2009
    ..This group proposes that genetic testing needs to be incorporated into daily clinical practice and also as an essential component of all ongoing and future clinical trials...
  12. ncbi Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence
    Maria T Di Martino
    Department of Experimental and Clinical Medicine, Magna Graecia University and Medical Oncology Unit, T Campanella Cancer Center, Salvatore Venuta University Campus Pathology Unit, Magna Graecia University, Catanzaro, Italy
    Clin Cancer Res 18:6260-70. 2012
    Deregulated expression of miRNAs has been shown in multiple myeloma (MM)...
  13. pmc Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma
    C I Jones
    Medical Research Building, Brighton and Sussex Medical School, University of Sussex, Falmer, Brighton BN1 9PS, UK
    Br J Cancer 107:1987-96. 2012
    b>Multiple myeloma is a plasma cell disorder that is characterised by clonal proliferation of malignant plasma cells in the bone marrow, monoclonal paraprotein in the blood or urine and associated organ dysfunction...
  14. ncbi Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells
    R Catlett-Falcone
    H Lee Moffitt Cancer Center and Research Institute, University of South Florida College of Medicine, Tampa 33612, USA
    Immunity 10:105-15. 1999
    ..STAT family member, Stat3, is constitutively activated in bone marrow mononuclear cells from patients with multiple myeloma and in the IL-6-dependent human myeloma cell line U266...
  15. pmc DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival
    Timothy R Peterson
    Whitehead Institute for Biomedical Research, Nine Cambridge Center, Cambridge, MA 02142, USA
    Cell 137:873-86. 2009
    ..Thus, we identify a novel mTOR-interacting protein whose deregulated overexpression in multiple myeloma cells represents a mechanism for activating PI3K/Akt signaling and promoting cell survival.
  16. pmc Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
    R A Kyle
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 23:3-9. 2009
    New systems have emerged for diagnosis, staging and response assessment in multiple myeloma (MM)...
  17. pmc DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma
    Nicola Amodio
    Department of Experimental and Clinical Medicine, Magna Graecia University and Medical Oncology Unit, T Campanella Cancer Center, Salvatore Venuta University Campus, Catanzaro, Italy
    Oncotarget 3:1246-58. 2012
    Aberrant DNA methylation plays a relevant role in multiple myeloma (MM) pathogenesis. MicroRNAs (miRNAs) are a class of small non-coding RNAs that recently emerged as master regulator of gene expression by targeting protein-coding mRNAs...
  18. ncbi Pathogenesis of myeloma
    Kenneth C Anderson
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Annu Rev Pathol 6:249-74. 2011
    b>Multiple myeloma (MM) is a neoplasm of post-germinal center, terminally differentiated B cells...
  19. ncbi Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer
    Dennis Löffler
    Institute of Clinical Immunology and Transfusion Medicine, Medical Faculty, University of Leipzig, Leipzig, Germany
    Blood 110:1330-3. 2007
    ..implicated in the pathogenesis of many malignancies and essential for IL-6-dependent survival and growth of multiple myeloma cells...
  20. pmc Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
    Esther A Obeng
    Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL 33101, USA
    Blood 107:4907-16. 2006
    b>Multiple myeloma (MM) is an incurable plasma cell malignancy. The 26S proteasome inhibitor, bortezomib, selectively induces apoptosis in MM cells; however, the nature of its selectivity remains unknown...
  21. ncbi Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
    Teru Hideshima
    Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Nat Rev Cancer 7:585-98. 2007
    b>Multiple myeloma is a plasma cell malignancy characterized by complex heterogeneous cytogenetic abnormalities. The bone marrow microenvironment promotes multiple myeloma cell growth and resistance to conventional therapies...
  22. pmc Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma
    W J Chng
    Department of Haematology Oncology, Mayo Clinic Comprehensive Cancer Center, Scottsdale, AZ, USA
    Leukemia 25:1026-35. 2011
    ..mediating transformation from the pre-malignant monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM) are unknown...
  23. pmc BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression
    Aldo M Roccaro
    Dana Farber Cancer Institute, Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Clin Invest 123:1542-55. 2013
    BM mesenchymal stromal cells (BM-MSCs) support multiple myeloma (MM) cell growth, but little is known about the putative mechanisms by which the BM microenvironment plays an oncogenic role in this disease...
  24. pmc miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1
    N Amodio
    Medical Oncology, Department of Experimental and Clinical Medicine, Magna Graecia University and T Campanella Cancer Center, Salvatore Venuta Campus, Catanzaro, Italy
    Cell Death Dis 3:e436. 2012
    MicroRNAs (miRNAs) with tumor-suppressor potential might have therapeutic applications in multiple myeloma (MM) through the modulation of still undiscovered molecular pathways...
  25. pmc Lenalidomide after stem-cell transplantation for multiple myeloma
    Philip L McCarthy
    Blood and Marrow Transplant Program, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    N Engl J Med 366:1770-81. 2012
    Data are lacking on whether lenalidomide maintenance therapy prolongs the time to disease progression after autologous hematopoietic stem-cell transplantation in patients with multiple myeloma.
  26. ncbi Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
    Philippe Moreau
    University Hospital, Nantes, France
    Lancet Oncol 12:431-40. 2011
    ..We compared the efficacy and safety of subcutaneous versus intravenous bortezomib at the approved 1·3 mg/m(2) dose and twice per week schedule in patients with relapsed multiple myeloma.
  27. pmc Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients
    Devi K Banerjee
    Laboratory of Cellular Physiology and Immunology, Rockefeller University, 1230 York Avenue no 176, New York, NY 10021, USA
    Blood 108:2655-61. 2006
    ..A single injection of cytokine-matured DCs led to rapid enhancement of FOXP3(+) Treg's in vivo in 3 of 3 myeloma patients. These data reveal a role for DCs in increasing the number of functional FOXP3(high) Treg's in humans...
  28. ncbi Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma
    David H Henry
    Joan Karnell Cancer Center, Philadelphia, PA 19106, USA
    J Clin Oncol 29:1125-32. 2011
    ....
  29. ncbi Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma
    Marta Lionetti
    Department of Medical Sciences, University of Milan, Milan, Italy
    Blood 114:e20-6. 2009
    To date, little evidence of miRNA expression/deregulation in multiple myeloma has been reported...
  30. pmc Characterization of clonogenic multiple myeloma cells
    William Matsui
    Sidney Kimmel Comprehensive Cancer Center, John Hopkins University School of Medicine, Bunting Blaustein Cancer Research Bldg, Rm 245, 1650 Orleans St, Baltimore, MD 21231, USA
    Blood 103:2332-6. 2004
    The identity of the cells responsible for the initiation and maintenance of multiple myeloma (MM) remains unclear largely because of the difficulty growing MM cells in vitro and in vivo...
  31. ncbi Epigenetic inactivation of the MIR34B/C in multiple myeloma
    Kwan Yeung Wong
    Department of Medicine, Queen Mary Hospital, University of Hong King, Pokfulam, Hong Kong
    Blood 118:5901-4. 2011
    ..that MIR34B/C, a direct transcriptional target of TP53, might be inactivated by promoter hypermethylation in multiple myeloma (MM)...
  32. ncbi Multiple myeloma
    Marc S Raab
    LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Lancet 374:324-39. 2009
    b>Multiple myeloma is characterised by clonal proliferation of malignant plasma cells, and mounting evidence indicates that the bone marrow microenvironment of tumour cells has a pivotal role in myeloma pathogenesis...
  33. pmc Multiple myeloma
    Robert A Kyle
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 111:2962-72. 2008
    b>Multiple myeloma is a clonal plasma cell malignancy that accounts for slightly more than 10% of all hematologic cancers...
  34. pmc PI3K/p110{delta} is a novel therapeutic target in multiple myeloma
    Hiroshi Ikeda
    LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Harvard Medical School, Boston, MA, USA
    Blood 116:1460-8. 2010
    In this study, we demonstrate expression and examined the biologic sequelae of PI3K/p110delta signaling in multiple myeloma (MM). Knockdown of p110delta by small interfering RNA caused significant inhibition of MM cell growth...
  35. pmc MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis
    Flavia Pichiorri
    Department of Molecular Virology, Ohio State University, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 105:12885-90. 2008
    Progress in understanding the biology of multiple myeloma (MM), a plasma cell malignancy, has been slow...
  36. pmc Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
    S Vincent Rajkumar
    Mayo Clinic, Rochester, Minnesota, USA
    Lancet Oncol 11:29-37. 2010
    High-dose dexamethasone is a mainstay of therapy for multiple myeloma. We studied whether low-dose dexamethasone in combination with lenalidomide is non-inferior to and has lower toxicity than high-dose dexamethasone plus lenalidomide.
  37. ncbi Continuous lenalidomide treatment for newly diagnosed multiple myeloma
    Antonio Palumbo
    Myeloma Unit, Division of Hematology, University of Turin, Azienda Ospedaliero Universitaria, S Giovanni Battista, Via Genova 3, 10126 Turin, Italy
    N Engl J Med 366:1759-69. 2012
    Lenalidomide has tumoricidal and immunomodulatory activity against multiple myeloma. This double-blind, multicenter, randomized study compared melphalan-prednisone-lenalidomide induction followed by lenalidomide maintenance (MPR-R) with ..
  38. pmc Classical and/or alternative NF-kappaB pathway activation in multiple myeloma
    Yulia N Demchenko
    Genetics Branch, National Cancer Institute, Bethesda, MD, USA
    Blood 115:3541-52. 2010
    Mutations involving the nuclear factor-kappaB (NF-kappaB) pathway are present in at least 17% of multiple myeloma (MM) tumors and 40% of MM cell lines (MMCLs)...
  39. pmc A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma
    Gullu Gorgun
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 115:5202-13. 2010
    Aurora-A is a mitotic kinase that regulates mitotic spindle formation and segregation. In multiple myeloma (MM), high Aurora-A gene expression has been correlated with centrosome amplification and proliferation; thus, inhibition of Aurora-..
  40. ncbi The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells
    T Hideshima
    Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 61:3071-6. 2001
    Human multiple myeloma (MM) is a presently incurable hematological malignancy, and novel biologically based therapies are urgently needed. Proteasome inhibitors represent a novel potential anticancer therapy...
  41. ncbi Review of 1027 patients with newly diagnosed multiple myeloma
    Robert A Kyle
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:21-33. 2003
    To determine the clinical and laboratory features of newly diagnosed multiple myeloma.
  42. ncbi The genetic architecture of multiple myeloma
    Gareth J Morgan
    Haemato Oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research and Royal Marsden Hospital, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
    Nat Rev Cancer 12:335-48. 2012
    ....
  43. ncbi Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome
    Herve Avet-Loiseau
    INSERM Unité 601, Laboratoire d Hematologie, Institut de Biologie, 9 quai Moncousu, 44093 Nantes, France
    Blood 109:3489-95. 2007
    ..In myeloma, the genomic aberrations t(4;14) and del(17p), together with beta2-microglobulin level, are important independent predictors of survival. These findings have implications for the design of risk-adapted treatment strategies...
  44. pmc Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
    Paul G Richardson
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 116:679-86. 2010
    ..Lenalidomide-bortezomib-dexamethasone demonstrates favorable tolerability and is highly effective in the treatment of newly diagnosed myeloma. This study is registered at http://clinicaltrials.gov as NCT00378105...
  45. pmc Molecular pathogenesis of multiple myeloma and its premalignant precursor
    W Michael Kuehl
    Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
    J Clin Invest 122:3456-63. 2012
    b>Multiple myeloma is a monoclonal tumor of plasma cells, and its development is preceded by a premalignant tumor with which it shares genetic abnormalities, including universal dysregulation of the cyclin D/retinoblastoma (cyclin D/RB) ..
  46. ncbi Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma
    Aristeidis Chaidos
    Centre for Haematology, Department of Medicine, Imperial College London, London, United Kingdom
    Blood 121:318-28. 2013
    ..of cells enriched in tumor-propagating activity and their relationship to the phenotypic architecture in multiple myeloma (MM) are controversial...
  47. pmc MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma
    Aldo M Roccaro
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Blood 113:6669-80. 2009
    Detailed genomic studies have shown that cytogenetic abnormalities contribute to multiple myeloma (MM) pathogenesis and disease progression...
  48. pmc The PP242 mammalian target of rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of rapamycin complex 1 (TORC1)/eukaryotic translation initiation factor 4E (eIF-4E)/RAF pathway and activ
    Bao Hoang
    Division of Hematology Oncology, UCLA GLA VA Healthcare System and Jonsson Comprehensive Cancer Center, Los Angeles, California 90073, USA
    J Biol Chem 287:21796-805. 2012
    ..Newer mTOR inhibitors (like pp242) can overcome feedback activation of AKT in multiple myeloma (MM) cells...
  49. ncbi DNA methylation of microRNA genes in multiple myeloma
    Kwan Yeung Wong
    Department of Medicine, Queen Mary Hospital, The University of Hong Kong Hong Kong, China
    Carcinogenesis 33:1629-38. 2012
    ..of tumor-suppressor miRNA genes by promoter DNA methylation has been implicated in human cancers, including multiple myeloma (MM)...
  50. pmc A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma
    Don M Benson
    Division of Hematology, The Ohio State University, Columbus, OH 43210 1240, USA
    Blood 120:4324-33. 2012
    Natural killer (NK) cells elicit cytotoxicity against multiple myeloma (MM); however, MM cells express HLA class I molecules as ligands to NK cell inhibitory killer immunoglobulin-like receptors (KIRs) as a means of immunoevasion...
  51. ncbi Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial
    Pieter Sonneveld
    Erasmus Medical Center, Rotterdam, The Netherlands
    J Clin Oncol 30:2946-55. 2012
    We investigated whether bortezomib during induction and maintenance improves survival in newly diagnosed multiple myeloma (MM).
  52. ncbi Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial
    Antonio Palumbo
    Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero Universitaria A O U S Giovanni Battista, Torino, Italy
    J Clin Oncol 28:5101-9. 2010
    The combination of bortezomib-melphalan-prednisone (VMP) is a new standard of care for newly diagnosed multiple myeloma. This phase III study examined the efficacy of the four-drug combination of bortezomib-melphalan-prednisone-..
  53. pmc A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
    David S Siegel
    John Theurer Cancer Center at Hackensack University, Hackensack, NJ 07601, USA
    Blood 120:2817-25. 2012
    ..next-generation, selective proteasome inhibitor being evaluated for the treatment of relapsed and refractory multiple myeloma. In this open-label, single-arm phase 2 study (PX-171-003-A1), patients received single-agent carfilzomib 20 ..
  54. ncbi Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial
    Jean Luc Harousseau
    Centre Rene Gauducheau, Nantes St Herblain, France
    J Clin Oncol 28:4621-9. 2010
    ..To compare efficacy and safety of bortezomib plus dexamethasone and vincristine plus doxorubicin plus dexamethasone (VAD) as induction before stem-cell transplantation in previously untreated myeloma...
  55. ncbi Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling
    N C Gutierrez
    Servicio de Hematologia, Hospital Universitario, Centro de Investigación del Cáncer IBMCC USAL CSIC, Salamanca, Spain
    Leukemia 24:629-37. 2010
    ..This finding prompted us to investigate potential associations between genetic abnormalities in multiple myeloma (MM) and singular miRNA expression profiles...
  56. ncbi Latest advances and current challenges in the treatment of multiple myeloma
    Anuj Mahindra
    Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA
    Nat Rev Clin Oncol 9:135-43. 2012
    Effectively treating patients with multiple myeloma is challenging...
  57. pmc Treatment of multiple myeloma
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Nat Rev Clin Oncol 8:479-91. 2011
    The treatment of multiple myeloma has changed dramatically in the past decade. The increase in the number of active agents has generated numerous possible drug combinations that can be used in the first-line and relapsed settings...
  58. pmc Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications
    Jana Jakubikova
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Department of Medical Oncology, Boston, MA, USA
    Blood 117:4409-19. 2011
    Recurrence of multiple myeloma (MM) after therapy suggests the presence of tumor-initiating subpopulations...
  59. ncbi Multiple myeloma
    Robert A Kyle
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    N Engl J Med 351:1860-73. 2004
  60. pmc The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells
    Eva Martinez-Garcia
    Division of Hematology Oncology, Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Blood 117:211-20. 2011
    The multiple myeloma SET domain (MMSET) protein is overexpressed in multiple myeloma (MM) patients with the translocation t(4;14)...
  61. ncbi A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
    John D Shaughnessy
    Donna D and Donald M Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 109:2276-84. 2007
    ..high-risk disease, we performed microarray analysis on tumor cells from 532 newly diagnosed patients with multiple myeloma (MM) treated on 2 separate protocols...
  62. ncbi Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6
    Marina Ratta
    Institute of Hematology and Medical Oncology, Lorenzo e Ariosto Seràgnoli, University of Bologna, Italy
    Blood 100:230-7. 2002
    ..concentration, phenotype, and function of peripheral blood (PB) dendritic cells (DCs) from patients with multiple myeloma (MM)...
  63. pmc The molecular classification of multiple myeloma
    Fenghuang Zhan
    Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 108:2020-8. 2006
    To better define the molecular basis of multiple myeloma (MM), we performed unsupervised hierarchic clustering of mRNA expression profiles in CD138-enriched plasma cells from 414 newly diagnosed patients who went on to receive high-dose ..
  64. pmc Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma
    Mariateresa Fulciniti
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 114:371-9. 2009
    Decreased activity of osteoblasts (OBs) contributes to osteolytic lesions in multiple myeloma (MM)...
  65. pmc Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene
    Apollina Goel
    Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 110:2342-50. 2007
    b>Multiple myeloma is a radiosensitive malignancy that is currently incurable...
  66. ncbi In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma
    Marc Beyer
    Molecular Tumor Biology and Tumor Immunology, Clinic I for Internal Medicine, University of Cologne, Joseph Stelzmann Strasse 9 Haus 16, 50931 Cologne, Germany
    Blood 107:3940-9. 2006
    ..in patients with premalignant monoclonal gammopathy of undetermined significance and patients with multiple myeloma that functional FoxP3(+) T(reg) cells of naive, central, and effector memory phenotype as determined by CCR7 ..
  67. ncbi Primary antitumor immune response mediated by CD4+ T cells
    Alexandre Corthay
    Institute of Immunology, University of Oslo, Rikshospitalet and Rikshospitalet University Hospital, 0027 Oslo, Norway
    Immunity 22:371-83. 2005
    ..These data indicate a mechanism for immunosurveillance of MHC-II-negative cancer cells by tumor-specific CD4+ T cells through collaboration with macrophages...
  68. ncbi Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter
    David Dingli
    Molecular Medicine Program, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Blood 103:1641-6. 2004
    ..requires further evaluation, image-guided radiovirotherapy is a promising new approach to the treatment of multiple myeloma, an incurable but highly radiosensitive plasma cell malignancy...
  69. ncbi Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma
    Thorsten Stühmer
    Department of Internal Medicine II, Division of Hematology and Oncology, University Clinics Würzburg, Germany
    Blood 106:3609-17. 2005
    Mutation of p53 is a rare event in multiple myeloma, but it is unknown if p53 signaling is functional in myeloma cells, and if targeted nongenotoxic activation of the p53 pathway is sufficient to kill tumor cells...
  70. ncbi Lenalidomide maintenance after stem-cell transplantation for multiple myeloma
    Michel Attal
    Department of Hematology, Hopital Purpan, Toulouse, France
    N Engl J Med 366:1782-91. 2012
    ..chemotherapy with autologous stem-cell transplantation is a standard treatment for young patients with multiple myeloma. Residual disease is almost always present after transplantation and is responsible for relapse...
  71. pmc CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy
    Abdel Kareem Azab
    Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Blood 113:4341-51. 2009
    The interaction of multiple myeloma (MM) cells with their microenvironment in the bone marrow (BM) provides a protective environment and resistance to therapeutic agents...
  72. pmc A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance
    Dharminder Chauhan
    Department of Medical Oncology, The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
    Cancer Cell 22:345-58. 2012
    ..therapy has proven successful for the treatment of relapsed/refractory, relapsed, and newly diagnosed multiple myeloma (MM); however, dose-limiting toxicities and the development of resistance limit its long-term utility...
  73. ncbi Efficacy and safety of once-weekly bortezomib in multiple myeloma patients
    Sara Bringhen
    Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero Universitaria S Giovanni Battista, Torino, Italy
    Blood 116:4745-53. 2010
    ..001). This improvement in safety did not appear to affect efficacy. This study is registered at http://www.clinicaltrials.gov as NCT01063179...
  74. ncbi The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma
    M A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    Leukemia 27:423-9. 2013
    The role of thalidomide, bortezomib and lenalidomide in multiple myeloma patients presenting with renal impairment was evaluated in 133 consecutive newly diagnosed patients who were treated with a novel agent-based regimen...
  75. pmc An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
    Ravi Vij
    Washington University School of Medicine, St Louis, MO 63110, USA
    Blood 119:5661-70. 2012
    ..elicited promising responses and an acceptable toxicity profile in patients with relapsed and/or refractory multiple myeloma (R/R MM)...
  76. ncbi miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF
    Chun Yan Sun
    Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
    Carcinogenesis 34:426-35. 2013
    ..In this study, we investigated the possible role of miR-15a/16 in the angiogenesis of multiple myeloma (MM)...
  77. ncbi The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma
    Kenneth C Anderson
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02115 5450, USA
    J Clin Oncol 30:445-52. 2012
    b>Multiple myeloma (MM) is a remarkable example of rapid bench-to-bedside translation in new drug development...
  78. ncbi Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma
    Brian A Walker
    Haemato Oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, London, UK
    Blood 120:1077-86. 2012
    ..These results are consistent with a distinct molecular pathogenesis underlying each subgroup and have important impacts on targeted treatment strategies. The Medical Research Council Myeloma IX trial is registered under ISRCTN68454111...
  79. ncbi Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis
    Alok C Bharti
    Cytokine Research Section, Department of Bioimmunotherapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 101:1053-62. 2003
    ..of the transcription factor nuclear factor-kappaB (NF-kappaB) in cell survival and proliferation in human multiple myeloma (MM), we explored the possibility of using it as a target for MM treatment by using curcumin (..
  80. ncbi Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3
    Michele Cavo
    Istituto di Ematologia Seragnoli, Universita degli Studi di Bologna, Bologna, Italy
    Lancet 376:2075-85. 2010
    ..aimed to assess the efficacy and safety of addition of bortezomib to TD (VTD) versus TD alone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma.
  81. ncbi Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders
    Andy C Rawstron
    HMDS, Leeds Teaching Hospitals NHS Trust, Leeds, UK
    Haematologica 93:431-8. 2008
    ....
  82. ncbi Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myelom
    Maria Victoria Mateos
    University Hospital of Salamanca, Salamanca, Spain
    Lancet Oncol 11:934-41. 2010
    ..VMP) is significantly better than melphalan plus prednisone alone for elderly patients with untreated multiple myeloma; however, toxic effects are high...
  83. ncbi Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma
    Teru Hideshima
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Mol Cancer Ther 10:2034-42. 2011
    ..the proteasome inhibitor bortezomib, have significantly improved the response and survival of patients with multiple myeloma over the last decade...
  84. pmc Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic Rochester, Minnesota 55905, USA
    Am J Hematol 87:78-88. 2012
    b>Multiple myeloma accounts for ∼10% of all hematologic malignancies.
  85. ncbi A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma
    Henk M Lokhorst
    University Medical Center, Utrecht, The Netherlands
    Blood 115:1113-20. 2010
    ..designed to evaluate the effect of thalidomide during induction treatment and as maintenance in patients with multiple myeloma who were transplant candidates...
  86. ncbi Importance of achieving a complete response in multiple myeloma, and the impact of novel agents
    Asher A Chanan-Khan
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    J Clin Oncol 28:2612-24. 2010
    The goal of treatment for multiple myeloma (MM) is to improve patients' long-term outcomes...
  87. pmc A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines
    Jerome Moreaux
    1INSERM, U847, Montpellier, France
    Haematologica 96:574-82. 2011
    b>Multiple myeloma is a plasma-cell tumor with heterogeneity in molecular abnormalities and treatment response.
  88. ncbi Molecular heterogeneity of multiple myeloma: pathogenesis, prognosis, and therapeutic implications
    Avet Loiseau Hervé
    University Hospital, Institut National de la Sante et de la Recherche Medicale U892, Nantes, France
    J Clin Oncol 29:1893-7. 2011
    b>Multiple myeloma (MM) is characterized by a significant heterogeneity at the molecular level. The first level is the chromosomal one...
  89. pmc The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
    Don M Benson
    Division of Hematology Oncology, The Ohio State University Medical Center, Columbus, OH, USA
    Blood 116:2286-94. 2010
    ..NK cells exert cytotoxicity against multiple myeloma (MM), an effect enhanced through novel therapies...
  90. pmc Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma
    Diana Cirstea
    Leebow Institute of Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Disease Center, Dana Farber Cancer Institute
    Mol Cancer Ther 9:963-75. 2010
    The phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway mediates multiple myeloma (MM) cell proliferation, survival, and development of drug resistance, underscoring the role of mTOR inhibitors, such as ..
  91. ncbi Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Am J Hematol 86:57-65. 2011
    b>Multiple myeloma is malignant plasma-cell disorder that accounts for ∼10% of all hematologic malignancies.
  92. pmc Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma
    Jacalyn Rosenblatt
    Beth Israel Deaconess Medical Center, Boston, MA, USA
    Blood 117:393-402. 2011
    ..We have completed a phase 1 study in which patients with multiple myeloma underwent serial vaccination with the DC/multiple myeloma fusions in conjunction with granulocyte-macrophage ..
  93. ncbi Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model
    Lori A Hazlehurst
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, at the University of South Florida, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Cancer Res 63:7900-6. 2003
    ....
  94. pmc Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells
    Siqing Wang
    Department of Lymphoma and Myeloma, Center for Cancer Immunology Research, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 108:4071-7. 2006
    ..Thus, this study has delineated the mechanistic defects of MoDCs from myeloma patients and identified ways for restoring the function of the cells to improve the efficacy of DC-based immunotherapy in this disease...
  95. ncbi Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma
    Pei Lin
    Department of Pathology and Laboratory Medicine, University of Arkansas for Medical Sciences, Little Rock, USA
    Am J Clin Pathol 121:482-8. 2004
    Bone marrow aspirates from 306 patients with multiple myeloma were analyzed by flow cytometric immunophenotyping...
  96. pmc Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma
    Craig D Peacock
    Sidney Kimmel Comprehensive Cancer Center and Department of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Proc Natl Acad Sci U S A 104:4048-53. 2007
    ..Here we study the role and mechanism of Hh pathway activation in multiple myeloma (MM), a malignancy with a well defined stem cell compartment...
  97. pmc Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
    H Quach
    Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria 3053, Australia
    Leukemia 24:22-32. 2010
    ....
  98. ncbi Phenotypic difference of normal plasma cells from mature myeloma cells
    H Harada
    Department of Internal Medicine, Hiroshima University, Japan
    Blood 81:2658-63. 1993
    ....
  99. pmc Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance
    William Matsui
    The Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Cancer Res 68:190-7. 2008
    Many agents are active in multiple myeloma, but the majority of patients relapse...
  100. ncbi Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress
    M Ri
    Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan
    Leukemia 24:1506-12. 2010
    Bortezomib is an effective agent for treating multiple myeloma (MM)...
  101. ncbi Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10
    R D Brown
    Institute of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
    Blood 98:2992-8. 2001
    ..Autologous high-potency DCs may have to be tested for CD80 up-regulation and biologically modified ex vivo before idiotype priming for immunotherapy...

Research Grants75

  1. NIEHS SUPPORT OF THE AHS COHORT STUDY AT NCI
    Charles Knott; Fiscal Year: 2010
    ..A cross-sectional study of pesticides and MGUS (a precursor of multiple myeloma) was published in 2009 showing AHS cohort members to be at twice the risk of MGUS compared to the general ..
  2. THE AGRICULTURAL HEALTH STUDY - FIELD STATIONS
    Charles Lynch; Fiscal Year: 2010
    ..A cross-sectional study of pesticides and MGUS (a precursor of multiple myeloma) was published in 2009 showing AHS cohort members to be at twice the risk of MGUS compared to the general ..
  3. Preclinical Development of JS-K, a Novel NO-Generating Prodrug for Cancer
    Paul J Shami; Fiscal Year: 2012
    ..tumors, JS-K is highly effective against acute myeloid leukemia, prostate cancer, hepatocellular carcinoma, multiple myeloma and non-small cell lung cancer...
  4. Inhibition of IkK to treat lethal Graft-vs.-Host Disease
    Patrick Flood; Fiscal Year: 2009
    ..allo-SCT) is potentially curative therapy for a patients suffering from leukemia, lymphoma and multiple myeloma. However, the problems associated with graft-versus-host disease (GVHD) have greatly limited the use of allo-..
  5. Gene-Engineered and Targeted Stem Cell Therapy for Myeloma
    Selvarangan Ponnazhagan; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Current advances in the treatment of multiple myeloma (MM) have resulted in a high rate of remissions;however, all patients eventually relapse and succumb to the disease...
  6. Cell death regulation in proteotoxic therapy
    Wei Xing Zong; Fiscal Year: 2013
    ..The proteasome inhibitor Bortezomib has been approved by FDA for treatment of multiple myeloma, and is being trialed in numerous cancers. However, the underlying molecular mechanisms remain elusive...
  7. Functional analysis of mDia formins in hematopoietic stem cell engraftment and mi
    Peng Ji; Fiscal Year: 2010
    ..such as aplastic anemia, fanconi anemia, sickle cell anemia, beta thalassemia major, leukemia, lymphomas, multiple myeloma, and many immune deficiency disorders...
  8. Using a MALDI-TOF System for SNP Analysis
    Nadereh Jafari; Fiscal Year: 2010
    ..b)identify susceptibility loci of Preterm Birth, c) validate the effect of DNA methylation in pathogenesis of Multiple Myeloma, d) Investigate the role of genetic polymorphisms in the TGF-ss signaling axis in the pathogenesis of ..
  9. Mechanistic validation of SCF E3 ligase as a cancer and radiosensitizing target
    Yi Sun; Fiscal Year: 2013
    ..and only) class of general proteasome inhibitor, approved by FDA for the treatment of relapsed/refractory multiple myeloma and mantle cell lymphoma...
  10. ATF4 and Osteoclastogenesis
    Guozhi Xiao; Fiscal Year: 2013
    ..intravenously administrated to reduce bone pain, hypercalcemia and skeletal complications in patients with multiple myeloma, breast, prostate, lung and other cancers and Paget's disease of bone, have a severe side effect called ..
  11. Use of Allogenicity to Stimulate Effector Responses Against Multiple Myeloma
    Christina N Johnson; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Multiple myeloma (MM) is a bone marrow plasma cell cancer with a mortality rate greater than 50%1...
  12. Genome Wide Admixture Scan for Multiple Myeloma in African Americans
    CHRISTOPHER ALAN HAIMAN; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Multiple myeloma (MM) is a malignancy consisting of a neoplastic clone of plasma cells, the terminally-differentiated B lymphocytes responsible for antibody production...
  13. Bioavailable proteasome inhibitors as broad-spectrum antivirals
    ALEXANDER NICLAS FREIBERG; Fiscal Year: 2013
    ..In 2003, the FDA approval of the first PSM Inb, Bortezomib, for the treatment of multiple myeloma, provided proof-of-principle that PSM Inbs can be developed with acceptable toxicology profile and good ..
  14. Analysis of mDia formins in hematopoietic stem cell engraftment and migration
    Peng Ji; Fiscal Year: 2013
    ..such as aplastic anemia, fanconi anemia, sickle cell anemia, beta thalassemia major, leukemia, lymphomas, multiple myeloma, and many immune deficiency disorders...
  15. GFI-1 and Osteoblast Suppression in Multiple Myeloma
    GARSON DAVID ROODMAN; Fiscal Year: 2013
    ..4) Determine if Gfi-1 deficiency in MSC in vivo prevents MM-induced suppression of OB differentiation. ..
  16. Molecular mechanisms of B cell malignant transformation
    Ping Xie; Fiscal Year: 2013
    ..splenic marginal zone lymphoma, B cell chronic lymphocytic leukemia and mantle cell lymphoma, as well as multiple myeloma (MM)...
  17. Radioimmunotherapy for Multiple Myeloma
    Damian J Green; Fiscal Year: 2013
    ..provided by applicant): Abstract: Despite the recent introduction of new and effective novel therapies for multiple myeloma (MM), the disease remains incurable...
  18. MOLECULAR MANIPULATION TO ENHANCE ANTI-MYELOMA RESPONSE
    Nikhil C Munshi; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): In our prior studies utilizing myeloma specific antigen (idiotype) and multiple myeloma (MM) cell-based vaccination, we observed induction of antigen-specific immune responses;however, clinical ..
  19. IL-15 Superagonist Complex as an Immunotherapeutic for Multiple Myeloma
    Hing C Wong; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Multiple myeloma (MM) is the second most commonly diagnosed hematologic malignancy with an estimated 20,520 newly diagnosed cases and 10,610 deaths due to MM in the United States in 2011...
  20. Vitamin D and Non-Hodgkin Lymphoma Prognosis
    Jennifer L Kelly; Fiscal Year: 2012
    ..Recent literature reports a potential impact of vitamin D on improved prognosis in colorectal cancer, multiple myeloma, breast cancer, and most recently diffuse large B cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL)..
  21. Quantitative Mass Spectrometry Assays to Detect Multiple Myeloma and Assess Relap
    JOHN MATTHEW KOOMEN; Fiscal Year: 2010
    ..In this proposal, mass spectrometry assays are developed to detect and quantify immunoglobulins from multiple myeloma patients, which will be compared with the current clinical techniques...
  22. Pharmacokinetics and Metabolism of Oxidized Curcumin
    Claus Schneider; Fiscal Year: 2013
    ..in multiple clinical trials for the prevention or treatment of cancers of the colon rectum, pancreas, multiple myeloma, and also for neurodegenerative diseases...
  23. Elucidating the role of microRNAs in the initiation of multiple myeloma
    Jianjun Zhao; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Multiple myeloma (MM) is a cancer characterized by colonial proliferation of plasma cells in bone marrow, lytic bone lesions, and serum monoclonal gammopathy...
  24. Ultrasound Ablation on Bone Cancer Under CT Fluoroscopy
    Everette C Burdette; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Metastatic bone cancer and multiple myeloma affects over 600,000 people every year in the United States and cause progressive bone destruction that results in severe pain, fractures, and the inability ..
  25. Prospective evaluation of IGF and IL-6 Dysregulation and Multiple Myeloma
    Graham A Colditz; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Multiple myeloma (MM) is a malignancy with poor survival and without known modifiable risk factors...
  26. Phase 1 of AR-42 in relapsed CLL, lymphoma, myeloma
    Craig C Hofmeister; Fiscal Year: 2012
    ..1) To perform a first-in-man study of AR-42 in relapsed lymphoma, chronic lymphocytic leukemia (CLL), and multiple myeloma patients in which patients will receive orally administered AR-42 Mon/Wed/Fri in cycles of 28 days (three ..
  27. High throughput screening assays to identify small molecules that target the ClpX
    Carolyn K Suzuki; Fiscal Year: 2010
    ..The proteasome has emerged as an important drug target in the treatment of multiple myeloma, and possibly other cancers...
  28. Transcriptional Functions and Targets of the MMSET Protein of t(4:14) Myeloma
    Jonathan Licht; Fiscal Year: 2013
    b>Multiple myeloma (MM) represents the malignant transformation of plasma cells, differentiated, post-germinal center B-cells adapted for the production of large quantities of antibody...
  29. Targeted Radiotherapy with 90Y-BC8 Monclonal Antibody, Fludarabine and TBI Follow
    William I Bensinger; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Important progress has been made in the treatment of patients with multiple myeloma (MM). Randomized trials of autologous stem cell transplant (ASCT) v...
  30. Hypersensitivity of Multiple Myeloma Bone Disease to Vitamin D
    GARSON DAVID ROODMAN; Fiscal Year: 2013
    ..applicant): Osteolytic bone disease is a major contributor to the morbidity and mortality caused by incurable multiple myeloma (MM)...
  31. Inhibitors of IgH Gene Enhancers for the Treatment of Multiple Myeloma
    FRANK W MARCOUX; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Multiple Myeloma (MM) is a deadly plasma cell malignancy...
  32. Protectides: A tool for drug target assays in myeloma
    Nancy L Allbritton; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Multiple myeloma is the second most common hematologic malignancy in the United States...
  33. DIFFERENTIATING AGENTS IN HEMATOLOGIC MALIGNANCIES
    Donald W Kufe; Fiscal Year: 2012
    ..PUBLIC HEALTH RELEVANCE: Hematologic malignancies, such as myeloid leukemia and multiple myeloma, are incurable in most patients...
  34. RECEPTOR TARGETED MOLECULAR IMAGING OF MULTIPLE MYELOMA
    Monica Shokeen; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Multiple myeloma (MM) is the second most commonly diagnosed hematologic cancer and remains incurable with current therapies...
  35. ChNKG2D-Targeted Cellular Cancer Therapy: Preclinical Toxicology
    CARIN MARIE LOUISE SENTMAN; Fiscal Year: 2010
    ..By 2020, it is projected to double again, and to triple by 2030. Multiple myeloma (MM) is a particularly deadly type of cancer...
  36. Mayo Comprehensive Cancer Center Grant
    Robert B Diasio; Fiscal Year: 2013
    ..Furthermore, there has been successful competitive renewal of 4 other SPOREs (Lymphoma, Prostate, Multiple Myeloma, Pancreas), as well as several multidisciplinary (P01, N01, 2 U01s, and 2 U10s) and 4 training grants...
  37. Proteolytic and chaperone machines implicated in virulence and disease
    Robert T Sauer; Fiscal Year: 2013
    ..Notably, inhibitors of the eukaryotic 20S peptidase are used to treat multiple myeloma and are active in animal models of autoimmune and inflammatory disease, and knowledge of which proteasomes ..
  38. ROLE OF ACA11, AN ORPHAN SMALL NUCLEOLAR RNA IN RESISTANCE TO CANCER CHEMOTHERAPY
    Jason Weber; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): The t(4;14) chromosomal translocation found in 20% of multiple myeloma (MM) cases leads to a shorter survival rate in an already incurable disease...
  39. Adoptive transfer of gene-modified autologous T-cells post-ASCT for myeloma
    Aaron P Rapoport; Fiscal Year: 2013
    ..We have conducted several trials of adoptive transfer T cell therapy for multiple myeloma, testing the hypothesis that improved T-cell recovery through intravenous infusion of ex-vivo CD28 ..
  40. Oral Mucosa Barrier and Bisphosphonate-related Osteonecrosis of the Jaw
    Ichiro Nishimura; Fiscal Year: 2013
    ..to be effective in the management of malignant neoplasms that reside in or metastasize to bone, including multiple myeloma and breast or prostate cancer, respectively...
  41. ANTI-INFLAMMATORY EFFECTS OF TARGETING THE HDAC6/HSP90 PATHWAY
    WAYNE WILLIAM HANCOCK; Fiscal Year: 2011
    ..are being developed for clinical application in neurodegenerative diseases ("polyglutaminopathies") and for multiple myeloma. By contrast, we have focused on how HDAC6, which unlike other HDACs, exists primarily in the cytoplasm, and ..
  42. CD38 Pretargeted Radioimmunotherapy for Myeloma
    Oliver W Press; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Multiple Myeloma (MM) is an incurable plasma cell malignancy that afflicts 66,000 Americans, with 20,580 new cases diagnosed each year...
  43. HTS for Rpn11 chemical probes
    Raymond J Deshaies; Fiscal Year: 2012
    ..active sites in the inner chamber of the proteasome can stem the progression of human cancers including multiple myeloma and mantle cell lymphoma...
  44. Radiovirotherapy for Multiple Myeloma
    Stephen J Russell; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Multiple myeloma was responsible for the deaths of more than 12,000 Americans in 2006 and remains incurable with current therapy...
  45. ENVIRONMENT &GENETICS OF MONOCLONAL GAMMOPATHY OF UNCERTAIN SIGNIFICANCE (MGUS)
    Michael H Tomasson; Fiscal Year: 2012
    ..an increased risk of osteoporosis and bone fractures and a risk of developing malignancy (predominantly multiple myeloma at 1% per year (REFS Kyle RA, NEJM, 2002)...
  46. Defining the mechanisms of secretion in the Drosophila salivary gland
    REBECCA MARIE FOX; Fiscal Year: 2010
    ..to the pathogenesis of many human diseases, including pancreatitis and diabetes, as well as the blood cancer, multiple myeloma. One key to understanding secretory organ development and function is to define the mechanisms whereby normal ..
  47. PROTEINS IN MULTIPLE MYELOMA AND RELATED BLOOD DISORDERS
    Alan Solomon; Fiscal Year: 2011
    ..The ultimate goal of this research is to improve the outcome of patients with AL amyloidosis, a medically devastating and ultimately fatal disease. ..
  48. Mouse Model of Age-Associated Monoclonal Gammopathy
    Peter Leif Bergsagel; Fiscal Year: 2013
    ..It is reported to progress to multiple myeloma (MM) at a rate of 2% per year...
  49. IKKa-Dependent Negative Feedback Control of Non-Canonical NF-kB Activation
    Genhong Cheng; Fiscal Year: 2012
    ..signaling can lead to a variety autoimmune and proliferative diseases including Systemic Lupus Erythematosus, Multiple Myeloma, and Diffuse B-cell Lymphoma...
  50. Molecular screen for isopeptidase inhibitors to treat pulmonary disease
    David E Sterner; Fiscal Year: 2011
    DESCRIPTION (provided by applicant): With the approval of the proteasome inhibitor Velcade for multiple myeloma therapy, the ubiquitin pathway has been validated for drug discovery...
  51. The Role of Oxidative Stress in Systemic Amyloidosis
    Steven R Zeldenrust; Fiscal Year: 2010
    ..involved in discerning the role of various cytokines, especially interleukin-1, in the pathogenesis of multiple myeloma. His laboratory and clinical expertise will greatly enhance this project...
  52. CD28-mediated Regulation of Multiple Myeloma Cell Proliferation and Survival
    Kelvin P Lee; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Multiple myeloma (MM) is a neoplasm of bone marrow (BM) resident plasma cells (PC) that comprises 20% of all hematologic malignancies, and despite new chemotherapeutic agents remains incurable...
  53. The role of ADAM10 in B cell development and humoral immunity
    NATALIA SOL CHAIMOWITZ; Fiscal Year: 2013
    ..in numerous B cell malignancies, including B cell chronic lymphocytic leukemia, Hodgkin's lymphoma and multiple myeloma. Thus, ADAM10 may be a target for the treatment of aberrant B cell development...
  54. 2012 CRTI Summer Workshop
    Mark Crowther; Fiscal Year: 2012
    ..clinical research in all areas of hematology, including the hematological malignancies (leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes, myeloproliferative neoplasms) and non-malignant hematology (bleeding and clotting ..
  55. Defining molecular biomarkers for CDK4/6-based cancer therapy by RNA sequencing
    CHRISTOPHER EDWARD MASON; Fiscal Year: 2013
    ..targeting CDK4/CDK6 with PD in combination with the proteasome inhibitor bortezomib (PDBo) in MCL and in multiple myeloma (MM)...
  56. Proteosome inhibitor sensitivity in multiple myeloma: The role of ER stress
    Lawrence H Boise; Fiscal Year: 2012
    b>Multiple myeloma is a neoplasia of plasma cells in the bone marrow and is presently an incurable disease...
  57. Pathogenesis of Monoclonal Gammopathy Bone Disease
    Matthew T Drake; Fiscal Year: 2013
    ..of plasma cell disorders which includes monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and multiple myeloma (MM). MGUS is the most common monoclonal gammopathy, affecting roughly 3...
  58. The role of miRNA15a and 16-1 in Multiple Myeloma
    Irene M Ghobrial; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Multiple Myeloma (MM) is the second most prevalent hematological malignancy and it remains incurable, with a median survival of 3-5 years...
  59. The Relationship Between Osteoporosis and Phenotypic Heterogeneity in COPD
    JESSICA BON FIELD; Fiscal Year: 2013
    ..Roodman, an authority on multiple myeloma and bone disease, combined with the robust research environment at the University of Pittsburgh, ensure the ..
  60. CXCR4 regulation of tumor progression in Multiple Myeloma
    Irene M Ghobrial; Fiscal Year: 2012
    ..Targeting this process by mobilizing myeloma cells out of the marrow will lead to a higher sensitivity to killing of the cells with cytotoxic agents. ..
  61. Integrin-targeted siRNA delivery for therapeutic gene silencing in blood cancers
    Timothy A Springer; Fiscal Year: 2013
    ..g., multiple myeloma)...
  62. Mouse models of age-associated monoclonal gammopathy
    PETER BERGSAGEL; Fiscal Year: 2009
    ..It is reported to progress to multiple myeloma (MM) at a rate of 2% per year...
  63. RANK-Associated Inhibitor (RAIN) in Osteoclast Formation
    Bryant Darnay; Fiscal Year: 2007
    ..rheumatoid arthritis, osteoporosis, giant cell tumor of bone, Paget's disease, metastatic breast cancer, multiple myeloma, and familial expansile osteolysis...
  64. Treatment decision making in older adults newly diagnosed with multiple myeloma
    Joseph D Tariman; Fiscal Year: 2010
    ..developing an intervention to promote active health care participation by older adults newly diagnosed with multiple myeloma. PROBLEM: Multiple myeloma is a B-cell malignancy of the plasma cells primarily affecting older adults with ..
  65. REGULATION OF PLASMA CELL MALIGNANCY BY INSULIN AND IGF
    GREGORY FREUND; Fiscal Year: 2000
    DESCRIPTION (Applicant's Description): Multiple myeloma is a malignant proliferation of plasma cells, and, as with all cancers, it is critical to understand the factors which promote its metabolism, growth and death...
  66. DRUG SEQUENCING RESISTANCE IN MULTIPLE MYELOMA
    Daniel Sullivan; Fiscal Year: 1999
    DESCRIPTION: (Applicant's Abstract) Multiple myeloma is an incurable disease with standard dose chemotherapy, having a median survival with treatment of about three years...
  67. IMMUNOGLOBULINS IN MULTIPLE MYELOMA & AMYLOIDOSIS
    Allen Edmundson; Fiscal Year: 1993
    ..be isolated from the sera (IgG and IgM immunogobulins) and urines (Bence-Jones proteins) of patients with multiple myeloma, amyloidosis and Waldenstrom's macroglobulinemia...
  68. A Novel Antibody Therapeutic for Multiple Myeloma
    Koteswara Chintalacharuvu; Fiscal Year: 2009
    b>Multiple myeloma is an incurable monoclonal proliferative disorder of malignant plasma cells affecting more than 14,000 persons in the U.S.A. per year...
  69. NOVEL SEROTHERAPY STRATEGIES--PLASMA CELL MALIGNANCIES
    STEVEN TREON; Fiscal Year: 2004
    Approximately 14,000 new cases of multiple myeloma (MM) and 1,500 new cases of Waldenstrom's Macroglobulinemia (WM) occur each year in the U.S...
  70. Curcumin/Bioperine in Multiple Myeloma
    Saroj Vadhan Raj; Fiscal Year: 2005
    ..However, curcumin has a poor oral bioavailability and optimal biologic dose has not been determined. Multiple myeloma is a clonal malignancy of plasma cells, affecting 13,000 of Americans each year...
  71. IL-12-Faciliated Hematopoietic Recovery Following Myeloablative Therapy
    Dan Douer; Fiscal Year: 2007
    ..in consolidation of front line chemotherapy for intermediate-high and high risk lymphoma, and in treating multiple myeloma. In some instances, this approach also may be beneficial in patients with acute myeloid leukemia in remission...
  72. ROLE OF VIL-6 IN PRIMARY EFFUSION LYMPHOMAS
    John Nicholas; Fiscal Year: 2004
    ..Recent reports indicate that HHV-8 may also be associated with multiple myeloma (MM)...
  73. Anti-TfR IgG3-Av: A New Drug Against Multiple Myeloma
    MANUEL PENICHET; Fiscal Year: 2009
    ..used alone or in combination with other agents as a novel drug against an incurable plasma cell malignancy: multiple myeloma (MM)...
  74. Endothelial Progenitor Cells in Multiple Myeloma
    Olcay Batuman; Fiscal Year: 2006
    b>Multiple myeloma (MM), which accounts for 1% of cancers and 2% of cancer deaths, is a liquid tumor characterized by expansion of monoclonal plasma cells and immunoglobulin (M protein) secretion...
  75. MECHANISMS OF DRUG RESISTANCE IN MULTIPLE MYELOMA
    William Dalton; Fiscal Year: 1990
    ..Recent preliminary evidence has shown that multiple drug resistance does develop in multiple myeloma, a tumor with a high initial chemotherapeutic response rate but virtually no cures...